Asset Manager

Updated:

CSL Behring

CSL Behring is a asset manager based in King of Prussia; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts...

CSL Behring

CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases.

General information

Firm type

Asset Manager

Location

Region

North America

Country

United States

City

King of Prussia

Corporate office

King of Prussia, PA, United States

Sector focus

BiotechHealthcare ServicesImmunologyHematologyCardiovascular and MetabolicRespiratoryTransplant

Frequently asked questions

Who runs investment decisions at CSL Behring?

CSL Behring is a business unit of CSL Limited, and its investment and R&D decisions are directed by the CSL executive leadership team. The firm does not publicly name individual portfolio managers or a CIO for CSL Behring specifically; strategic direction comes from the parent company's board and management (per CSL's investor relations).

How does CSL Behring source proprietary deal flow?

CSL Behring primarily sources R&D opportunities internally via its three scientific platforms. Additionally, it engages in partnerships and acquisitions for drug candidates; examples include the acquisition of Vita Therapeutics and collaborations with academic institutions (per the firm's pipeline disclosures).

Does CSL Behring participate in fund commitments or only direct deals?

CSL Behring does not participate in third-party fund commitments. All capital deployment is direct, focusing on internal drug development, manufacturing scale-up, and strategic acquisitions that align with its therapeutic areas (per CSL filings).

Which sectors does CSL Behring explicitly avoid?

CSL Behring focuses exclusively on biotherapeutics for rare and serious diseases within immunology, hematology, cardiovascular and metabolic, respiratory, and transplant areas. It does not invest in other sectors such as digital health, medical devices, diagnostics, or industrial biotechnology (per firm website).

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More King of Prussia Asset Manager profiles